Paul Perreault
-

Boathouse Row to Light Up for Rare Disease Day, Says King of Prussia’s CSL Behring CEO
“Our collective hope shines a light on the progress made and challenges ahead,” CSL Behring Limited CEO and Managing Director Paul…
-

King of Prussia’s CSL Behring to Acquire Calimmune for $91M
King of Prussia’s biotherapeutics company CSL Behring is acquiring Calimmune, a clinical-stage biotechnology company, for $91 million, writes Linda Loyd…
-

CEO of King of Prussia’s CSL Ltd. Discusses Impact of Gene Therapy
Paul Perreault, the 59-year-old chief executive officer and managing director of CSL Ltd., recently discussed with the Philadelphia Inquirer the…





















![ForAll_Digital-Ad_Malaika_376x628[44]](https://montco.today/wp-content/uploads/sites/2/2022/06/ForAll_Digital-Ad_Malaika_376x62844.jpg)









